You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Shure Incorporated v. Clearone, Inc. (D. Del. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Shure Incorporated v. Clearone, Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Shure Incorporated v. ClearOne, Inc. | 1:19-cv-01343

Last updated: February 8, 2026

Overview

Shure Incorporated filed a patent infringement lawsuit against ClearOne, Inc. (docket 1:19-cv-01343) in the United States District Court for the District of Utah. The case concerns patents related to audio conferencing and signal processing technology. The litigation spans from the complaint filed in 2019 through subsequent procedural developments, including motions, discovery, and settlement discussions.

Case Timeline

  • September 25, 2019: Shure files complaint alleging infringement of U.S. Patent Nos. 9,839,412; 10,263,600; and 10,598,991. The patents cover digital audio signal processing methods and systems used in conference room microphones and related devices.

  • October 2019 - December 2019: ClearOne responds with an answer denying infringement. The parties exchange initial disclosures and conduct early discovery, focusing on technical claim construction and patent validity.

  • 2020: Both sides file multiple motions. Shure seeks injunctive relief and damages, while ClearOne challenges patent validity via motions for summary judgment. The parties enter settlement negotiations.

  • 2021: The case proceeds with contested claim construction, and a Markman hearing takes place in early 2021. The court issues its claim construction order, narrowing the scope of patent claims.

  • 2022: Discovery continues, with depositions of key technical witnesses. Both parties file motions for summary judgment on infringement and validity. The court schedules trial but indicates willingness to mediate.

  • 2023: Mediation attempts occur but do not resolve the case. The court maintains the trial schedule. No disposition has been publicly recorded as of late 2023.

Technical and Patent Litigation Details

  • Patents Involved:

    • U.S. Patent No. 9,839,412: Covers methods for digital audio signal processing to improve audio clarity in conferencing environments.

    • U.S. Patent No. 10,263,600: Relates to systems for adaptive audio signal processing based on user environment.

    • U.S. Patent No. 10,598,991: Focuses on noise reduction and echo cancellation techniques in digital audio devices.

  • Allegations:

    • Shure alleges ClearOne’s audio conferencing devices directly infringe on the patents by incorporating patented signal processing algorithms.

    • Claim charts submitted estimate infringement across multiple ClearOne product lines, including audio processors and conference microphones.

  • Defenses:

    • ClearOne contends the patents are invalid due to prior art and obviousness.

    • ClearOne disputes infringement, arguing its products do not incorporate the patented algorithms as claimed.

Key Legal Issues

  • Patent Validity: Tests for obviousness and anticipation under 35 U.S.C. §§ 102 and 103. ClearOne questioned the novelty of the patents based on prior art references.

  • Infringement: Whether ClearOne’s products contain each element of the patented claims. Claim construction played a vital role.

  • Injunctive Relief and Damages: Shure seeks monetary compensation and an injunction against ClearOne’s sales.

  • Procedural Motions: Disputes over claim scope, Daubert motions on expert testimony, and summary judgment motions on infringement and validity.

Current Status

As of late 2023, the case remains ongoing with no final judgment. Both parties prepare for trial, with discovery largely completed. No appeal has been filed, but settlement remains a possibility.

Implications for Industry

  • The case illustrates patent enforcement efforts by Shure against competitors in the conferencing device segment.

  • Validity challenges highlight the importance of robust patent prosecution strategies amid rapidly evolving audio technology.

  • The outcome could influence licensing negotiations and product design considerations for companies in digital audio equipment.


Key Takeaways

  • Patent infringement litigation involving audio signal processing patents exists amid intense industry competition.
  • The case hinges on claim construction, validity, and technical feature distinctions.
  • Ongoing legal actions and potential settlement could impact market deployments and licensing.
  • Technical patent claims in digital audio devices face challenges from prior art and obviousness arguments.
  • The litigation underscores the importance of clear patent drafting and innovation documentation.

FAQs

1. What patents does Shure allege ClearOne infringed?
Shure claims infringement of three patents: Nos. 9,839,412; 10,263,600; and 10,598,991, all related to digital audio signal processing for conferencing.

2. What are the main defenses used by ClearOne?
ClearOne disputes infringement and challenges the patents' validity based on prior art, asserting the patents are obvious or anticipated.

3. Has there been a ruling on the validity of these patents?
No final ruling on validity has been issued. The case is ongoing with validity defenses under active litigation.

4. How might this case affect the audio conferencing industry?
A ruling favoring Shure could lead to licensing agreements, while a victory for ClearOne might affirm broader product development flexibility. The case signals increased patent enforcement efforts.

5. Could this case influence future patent strategies?
Yes. Companies may place greater emphasis on patent claim clarity and robustness, especially in rapidly evolving digital signal processing fields.


References:

  1. Court docket and filings for Shure Incorporated v. ClearOne, Inc., 1:19-cv-01343, District of Utah.
  2. Patent documents and prior art references discussed in the case filings.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.